–
Статьи в журналах
-
- 2021 Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
- Galle Peter R., Finn Richard S., Qin Shukui, Ikeda Masafumi, Zhu Andrew X., Kim Tae-You, Kudo Masatoshi, Breder Valeriy, Merle Philippe, Kaseb Ahmed, Li Daneng, Mulla Sohail, Verret Wendy, Xu Derek-Zhen, Hernandez Sairy, Ding Beiying, Liu Juan, Huang Chen, Lim Ho Yeong, Cheng Ann-Lii, Ducreux Michel
- в журнале Lancet Oncology, издательство The Lancet Publishing Group (United Kingdom), том 22, № 7, с. 991-1001 DOI